AR110642A1 - Pastilla de liberación controlada basada en alcohol de polivinilo y su fabricación - Google Patents

Pastilla de liberación controlada basada en alcohol de polivinilo y su fabricación

Info

Publication number
AR110642A1
AR110642A1 ARP170103081A ARP170103081A AR110642A1 AR 110642 A1 AR110642 A1 AR 110642A1 AR P170103081 A ARP170103081 A AR P170103081A AR P170103081 A ARP170103081 A AR P170103081A AR 110642 A1 AR110642 A1 AR 110642A1
Authority
AR
Argentina
Prior art keywords
polyvinyl alcohol
powder
range
manufacturing
controlled release
Prior art date
Application number
ARP170103081A
Other languages
English (en)
Inventor
Anja Knuettel
- Di Gallo Nicole Nadine
Zheng Mengyao Dr
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschraenkter Haftung filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of AR110642A1 publication Critical patent/AR110642A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Reivindicación 1: Polvo de alcohol de polivinilo (PVA) que comprende polvo, caracterizado porque muestra una fluidez y viabilidad en la compresión directa en forma de pastillas luego de la extrusión y trituración hasta la obtención de tamaños de partículas en el rango de £ 200 mm (d₅₀), con preferencia en el rango de 60 a 120 mm (d₅₀), con mayor preferencia aún en el rango de 70 a 110 mm (d₅₀). Reivindicación 7: Una composición en polvo para la preparación de formulaciones en pastillas, caracterizada porque comprende: a) polvo de alcohol de polivinilo de acuerdo con una o más de las reivindicaciones 1 a 6 como vehículo, que es un polvo extruido y triturado en forma homogénea, b) al menos un ingrediente farmacéuticamente activo (API), y c) opcionalmente otros aditivos, mediante los cuales este polvo triturado se puede almacenar y transportar en forma estable.
ARP170103081A 2016-11-07 2017-11-07 Pastilla de liberación controlada basada en alcohol de polivinilo y su fabricación AR110642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16197610 2016-11-07

Publications (1)

Publication Number Publication Date
AR110642A1 true AR110642A1 (es) 2019-04-17

Family

ID=57241028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103081A AR110642A1 (es) 2016-11-07 2017-11-07 Pastilla de liberación controlada basada en alcohol de polivinilo y su fabricación

Country Status (12)

Country Link
US (1) US20190274961A1 (es)
EP (1) EP3534881A1 (es)
JP (1) JP2019534293A (es)
KR (1) KR20190082848A (es)
CN (1) CN110198704A (es)
AR (1) AR110642A1 (es)
AU (1) AU2017352556A1 (es)
BR (1) BR112019009159A2 (es)
CA (1) CA3042769A1 (es)
MX (1) MX2019005302A (es)
PH (1) PH12019500610A1 (es)
WO (1) WO2018083285A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110234666A (zh) * 2016-12-28 2019-09-13 株式会社可乐丽 含有侧链烯烃的乙烯醇类聚合物及其制造方法
KR20230098278A (ko) 2020-10-28 2023-07-03 메르크 파텐트 게엠베하 난용성 활성 약학 성분의 용해도를 향상시키기 위한 약학 조성물 및 방법
US20230398222A1 (en) 2020-10-28 2023-12-14 Merck Patent Gmbh Method for producing an amorphouse solid dispersion and pharmaceutical composition for stabilizing active pharmaceutical ingredients
WO2022090295A1 (en) 2020-10-28 2022-05-05 Merck Patent Gmbh Method for producing an amorphous solid dispersion and pharmaceutical composition for stabilizing active pharmaceutical ingredients
CN112980058B (zh) * 2021-02-19 2022-12-02 南京百思福医药科技有限公司 共研磨法制备壳聚糖衍生物与pva共混物及其应用
WO2023138366A1 (zh) * 2022-01-19 2023-07-27 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
WO2023171730A1 (ja) * 2022-03-10 2023-09-14 三菱ケミカル株式会社 医薬用組成物、医薬錠剤およびその製造方法
WO2024008604A1 (en) 2022-07-06 2024-01-11 Merck Patent Gmbh Pharmaceutical composition and method for enhancing solubility of poorly soluble active pharmaceutical ingredients
WO2024056773A1 (en) 2022-09-16 2024-03-21 Merck Patent Gmbh Spray-dried amorphous solid dispersions and method for preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2542346B2 (ja) 1987-05-30 1996-10-09 日本合成化学工業株式会社 高重合度ポリビニルアルコ−ルの製造法
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
DE102007026166A1 (de) * 2007-06-04 2008-12-11 Kuraray Europe Gmbh Verfahren zur thermoplastischen Formgebung von Polyvinylalkohol und hiermit hergestellte Formkörper oder Granulate
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
JP5612279B2 (ja) * 2009-06-26 2014-10-22 日本合成化学工業株式会社 心筋梗塞非ヒト動物モデル及びその作製方法
WO2016013675A1 (ja) * 2014-07-25 2016-01-28 日本合成化学工業株式会社 ポリビニルアルコール微粒子、それを用いた医薬用結合剤、医薬錠剤、徐放性医薬錠剤及びポリビニルアルコール微粒子の製造方法
CN106659793A (zh) * 2014-07-30 2017-05-10 默克专利股份有限公司 粉状可直接压制的聚乙烯醇类
JP2016079142A (ja) * 2014-10-20 2016-05-16 日本合成化学工業株式会社 ポリビニルアルコール含有顆粒の製造方法
US20180280302A1 (en) * 2015-01-20 2018-10-04 Merck Patent Gmbh Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer

Also Published As

Publication number Publication date
CA3042769A1 (en) 2018-05-11
MX2019005302A (es) 2019-08-12
CN110198704A (zh) 2019-09-03
JP2019534293A (ja) 2019-11-28
AU2017352556A1 (en) 2019-06-20
PH12019500610A1 (en) 2019-12-02
WO2018083285A1 (en) 2018-05-11
KR20190082848A (ko) 2019-07-10
US20190274961A1 (en) 2019-09-12
BR112019009159A2 (pt) 2019-07-16
EP3534881A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
AR110642A1 (es) Pastilla de liberación controlada basada en alcohol de polivinilo y su fabricación
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
PE20150762A1 (es) Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
EA201690810A1 (ru) Мягкие пастилки, содержащие экстракт куркумы
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
MX2016012846A (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
CL2016000510A1 (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
GT201700138A (es) Pirazolpiridinaminas
CR20150455A (es) Imidazopiridazinas sustituidas
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20180036A1 (es) Inhibidores de bromodominio
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
AR095132A1 (es) Formulación en dispersión sólida de un compuesto antiviral
IN2015DN00637A (es)
CO2023013397A2 (es) Compuestos de tienopirrol
CL2016001350A1 (es) Composiciones de ketoprofeno de accion prologanda.
PE20160238A1 (es) Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
AR097202A1 (es) Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa
AR100625A1 (es) Formulación de ceritinib
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure